- Trial Phase
- Approved
- Time to Market
- Already approved and marketed since October 2021. The drug's continued availability depends on the outcome of the FDA hearing on the proposed withdrawal of approval.
- Why 4/10
- TAVNEOS is an approved, marketed drug facing a proposed FDA withdrawal. The next binary catalyst is the FDA hearing on the withdrawal, for which Amgen submitted its request on July 23, 2026, but no hearing date has been publicly set. Because TAVNEOS represents only about 1% of Amgen's total revenue and Amgen is a diversified large-cap biotech, even a definitive outcome would not drive a large share-price move, capping the impact score at 4.
The next catalyst is the FDA hearing on the proposed withdrawal of TAVNEOS approval. Amgen submitted its hearing request on July 23, 2026, but no hearing date has been publicly set. If the FDA ultimately withdraws approval, TAVNEOS revenue (about $105M/quarter, ~1% of Amgen's total) would be lost, but the impact on Amgen's diversified $250B market cap would be modest. A positive outcome preserving the drug would remove a regulatory overhang but is unlikely to materially move the stock given the drug's small revenue contribution.
Price Chart
Executive Summary
TAVNEOS (avacopan) is an oral C5a receptor antagonist approved by the FDA in October 2021 for severe active ANCA-associated vasculitis, a rare autoimmune disease. Originally developed by ChemoCentryx (acquired by Amgen for ~$3.7B in 2022), the drug generated about $105M in Q3 2026 sales. However, TAVNEOS is in deep regulatory trouble: in April 2026 the FDA proposed withdrawing its approval, citing manipulated trial data and liver safety concerns including 76 injury cases and 8 deaths. The NEJM retracted the pivotal ADVOCATE trial in June 2026, the EU revoked marketing authorization in August 2026, and the UK suspended it for new patients. Amgen has requested an FDA hearing to defend the drug, but no hearing date has been set. TAVNEOS remains available in the US pending the outcome. For Amgen, a $250B diversified biotech, TAVNEOS represents roughly 1% of total revenue, so the financial impact of a withdrawal would be manageable.
How It Works
TAVNEOS (avacopan) is an oral capsule that blocks the C5a receptor, a key part of the immune system's complement cascade that drives inflammation. In ANCA-associated vasculitis, the immune system mistakenly attacks blood vessels. By blocking C5a, TAVNEOS reduces this inflammatory damage and allows patients to reduce their use of high-dose steroids (glucocorticoids).
Trial Status
TAVNEOS was approved based on the Phase 3 ADVOCATE trial (NCT02994927). The NEJM retracted the ADVOCATE publication in June 2026 after the FDA found evidence of data manipulation, including unblinded re-adjudication of outcomes. Real-world evidence studies have since been published showing higher remission rates than the trial, though these are observational.
The Two-Sided Case
Upcoming Catalysts
- FDA hearing on proposed withdrawal of TAVNEOS approval (no date publicly set as of Nov 4, 2026)
- Potential FDA final decision on whether to withdraw or maintain approval
- Japan PMDA review of potential cancellation of approval
- Australia TGA review of benefits and risks (withdrawal planned for March 2027)
- Product liability litigation developments
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report